Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

ID: 4184252

A biopharmaceutical company focusing on the discovery, development, and commercialization of RNAi therapeutics for treating rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS) diseases.

7

Funding Rounds

$886.1m

Money raised

Overview

A biopharmaceutical company focusing on the discovery, development, and commercialization of RNAi therapeutics for treating rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS) diseases.

Unlock Complete Company Intelligence

Access comprehensive data and insights available only to Seedtable members

Financial Details

  • • Complete funding history and valuations
  • • Revenue estimates and financial metrics
  • • Investment round details and terms

People & Contacts

  • • Complete leadership team profiles
  • • Contact information and email addresses
  • • Board members and advisors

Market Intelligence

  • • Competitive landscape analysis
  • • Market position and growth metrics
  • • Industry benchmarking data

Premium Tools

  • • Export data and generate reports
  • • Save companies to custom watchlists
  • • API access for data integration

Join 10,000+ Professionals

Trusted by investors, founders, and analysts worldwide

Access detailed insights on 71,000+ companies worldwide

Funding

Funding series

Funding Series Analysis

The company Alnylam Pharmaceuticals has raised a total of $886.1m in funding over 7 rounds.

Key Insights:

  • Alnylam Pharmaceuticals Private equity, April 2020: $100m
  • Alnylam Pharmaceuticals Private equity, April 2020: $750m
  • Alnylam Pharmaceuticals Private equity, April 2019: $800k
  • Alnylam Pharmaceuticals Private equity, January 2014: $700k
  • Alnylam Pharmaceuticals funding round, March 2011: $10m
  • Alnylam Pharmaceuticals Venture round, July 2003: $24.6m